Clinical Trial Update: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for MK-3475-01A/KEYMAKER-U01A evaluating pembrolizumab with or without chemotherapy in treatment-naïve Stage IV non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: RECRUITING